Streptococcus pneumoniae inflicts a huge disease burden as the leading cause of
community-acquired pneumonia and meningitis. Soon after mainstream antibiotic usage …

Background Approximately 800,000 children die each year due to pneumococcal disease
and> 90% of these deaths occur in develo** countries where few children have access to …

Background Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was
inferred before licensure from an aggregate correlate of protection established for the seven …

Background In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13 …

ContextAs the epidemiology of infections with methicillin-resistant Staphylococcus aureus
(MRSA) changes, accurate information on the scope and magnitude of MRSA infections in …

Background: The test-negative design is an increasingly popular approach for estimating
vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test …

SUMMARY On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein
conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer …

The immunogenicity of polysaccharides as human vaccines was enhanced by coupling to
protein carriers. Conjugation transformed the T cell-independent polysaccharide vaccines of …

Background Routine infant immunisation with seven-valent pneumococcal conjugate
vaccine (PCV7) began in the USA in 2000. Although invasive pneumococcal disease has …

Background Invasive pneumococcal disease declined among children and adults after the
introduction of the pediatric heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 …